Abnormalities of factor VIII and platelet aggregation: use of ristocetin in diagnosing the von Willebrand syndrome

Abstract

Ristocetin was used to study platelet aggregation in platelet rich plasma and to assay the von Willebrand factor activity of factor VII (VIII(vwf)). Ristocetin induced platelet aggregation (RIPA) was decreased in 13 of 18 patients with van Willebrand's disease (VWD) who had decreased plasma levels of VIII(vwf). The 5 patients with normal RIPA appeared to have mild VWD but did not constitute a separate subclass. RIPA was also abnormal in some patients with intrinsic platelet defects, but in no case was the defect corrected by normal plasma. The latter type of correction appears to be specific for VWD. Aspirin ingestion inhibited the second phase of RIPA (at low concentrations of ristocetin only) but did not affect the initial phase of aggregation or the level of VIII(vwf). The authors also studied a group of patients who had both abnormalities of the factor VIII complex and intrinsic platelet defects, such as impaired collagen induced aggregation. The findings in these patients and in those with typical von Willebrand's disease appear to comprise a spectrum of disorders (von Willebrand syndrome) in which some abnormality of the factor VIII complex is associated with impaired platelet function. At present, ristocetin would appear to be a useful reagent for evaluating patients with bleeding disorders and for studying patients with the von Willebrand's syndrome.